Compare Northrop Grumman Corporation (NOC) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Northrop Grumman Corporation vs Smith & Nephew plc — how do they compare? Northrop Grumman Corporation trades at $481.28 (market cap $68.83B), while Smith & Nephew plc trades at $27.17 (market cap $11.10B). The key difference: Northrop Grumman Corporation is far larger — about 6.2× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Northrop Grumman Corporation for 81 Days and Smith & Nephew plc for 120 Days on average.
| NOC | SNN | |
|---|---|---|
Market Cap | $68.83B | $11.10B |
Volume | 1,081,989 | 1,051,703 |
Sector | Industrials | Health |
52-Week High | $768.02 | $37.17 |
52-Week Low | $473.46 | $26.42 |
Typical Hold Time | 81 Days | 120 Days |
Enterprise Value | $82.81B | $14.13B |
Dividend Yield | 2.04% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Northrop Grumman (NOC) trades at $473.46, down 2.0% on the day, reflecting a bearish technical signal amid recent contract loss news. The stock exhibits strong fundamentals with a P/E of 15.05, net income margin of 10.48%, and consistent earnings beats in recent quarters. Revenue growth is steady, supported by a record backlog, though the loss of the $20 billion Navy F/A-XX contract to Boeing introduces competitive pressure.
The outlook remains supported by robust defense budgets and key programs like the B-21 bomber, but investor sentiment is cautious near-term. Analyst consensus is bullish with a $600.62 price target, though technical indicators suggest potential near-term weakness. Risks include contract dependencies and macroeconomic shifts in defense spending.
Smith & Nephew (SNN) trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio, though the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show profitability growth, the stock's proximity to lows and mixed analyst sentiment (26% buy, 65% hold) suggest limited near-term upside. Key risks include competitive pressures and execution challenges, but the stable dividend and institutional interest offer some support for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
